Bibliography
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Publishing, Arlington; 2013
- National Institute on Drug Abuse. The clinical assessment of substance use disorders. 2014. Available from: http://www.drugabuse.gov/nidamed/centers-excellence/resources/clinical-assessment-substance-use-disorders [Last accessed 28 July 2014]
- Koob GF. Addiction is a reward deficit and stress surfeit disorder. Front Psychiatry 2013;4:1-18
- Satel S, Lilienfeld SO. Addiction and the brain-disease fallacy. Front Psychiatry 2014;4:1-11
- Cunningham JA. Addiction: many factors contribute. Nature 2014;507:40
- Heim D. Addiction: not just brain malfunction. Nature 2014;507:40
- Spillane J, McAllister WB. Keeping the lid on: a century of drug regulation and control. Drug Alcohol Depend 2003;70:S5-S12
- Goldstein MB, Engwall DB. The politics of prevention: changing definitions of substance use/abuse. J Health Soc Policy 1992;3:69-83
- Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79
- United States Department of Justice. The economic impact of illicit drug use on American society. 2011. Available from: www.justice.gov/archive/ndic/pubs44/44731/44731p.pdf [Last accessed 28 July 2014]
- Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;9:1575-86
- Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1564-74
- Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70
- Ferrari AJ, Norman RE, Freedman G, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. PLoS One 2014;9:e91936
- Dolgin E. Straight talk with... George Koob. Nat Med 2014;20(1):8
- Van den Brink W, Montgomery SA, Van Ree JM, et al. ECNP consensus meeting March 2003. Guidelines for the investigation of efficacy in substance use disorders. Eur Neuropsychopharmacol 2006;16:224-30
- World Health Organization. Regional strategy on mental health and substance abuse. 2012. Available from: http://applications.emro.who.int/dsaf/emropub_2012_EN_1067.pdf [Last accessed 28 July 2014]
- de Leon-Casasola OA. Opioids for chronic pain: new evidence, new strategies, safe prescribing. Am J Med 2013;126:S3-S11
- Swedberg MDB. A proactive nonclinical drug abuse and dependence liability assessment strategy: a sponsor perspective. Behav Pharmacol 2013;24:396-402
- Gad SC. Safety and regulatory requirements and challenge for CNS drug development. Neurobiol Dis 2014;61:39-46
- Calderon SN, Klein M. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. Neuropharmacology 2014. [Epub ahead of print]
- Higgins J, Cartwright ME, Templeton AC. Foundation review: progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure. Drug Discov Today 2012;17:828-36
- Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of LU AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340:666-75
- Schultz W. Updating dopamine reward signals. Curr Opin Neurobiol 2013;23:229-38
- Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. JAMA 2009;301:1148-54
- Turner JR, Gold A, Schnoll R, et al. Translational research in nicotine dependence. Cold Spring Harb Perspect Med 2013;3(3):a012153
- Nutt DJ, Lingford-Hughes A, Chick J. Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments? J Psychopharmacol 2012;26:199-204
- Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies– tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-6
- Douaihy AB, Kelly TM, Sullivan C. Medications for substance use disorders. Soc Work Public Health 2013;28:264-78
- Koob GF, Lloyd GK, Mason BJ. Development of pharmacotherapies for drug addiction, a Rosetta Stone approach. Nat Rev Drug Discov 2009;8:500-15
- van den Brink W, Mann K, Gual A, Aubin HJ. Re: Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency. BMJ 2014; published online April 2014; https://doi.org/10.1136/bmj.g2605 doi:10.1136/bmj.g2605
- European Medicines Agency. Summary of opinion (initial authorisation). Selincro. Nalmefene. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002583/WC500136280.pdf [Last accessed 28 July 2014]
- U.S. Food and Drug Administration. FY 1995 PDUFA Performance Report. 2011. Available from: http://www.fda.gov/aboutfda/reportsmanualsforms/reports/userfeereports/performancereports/ucm117257.htm [Last accessed 28 July 2014]
- U.S. Food and Drug Administration. FDA Daily Digest Bulletin, Wednesday, July 9. 2008. Available from: http://fda-online.blogspot.com/2008/07/us-food-drug-administration-fda-daily_10.html [Last accessed 28 July 2014]
- Phillips KA, Epstein DH, Preston KL. Psychostimulant addiction treatment. Neuropharmacology 2014. [Epub ahead of print]
- Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am 2014;32:1-28
- Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9:203-14
- Palmer AM, Alavijeh MS. Translational CNS medicines research. Drug Discov Today 2012;17:1068-78
- Talevi A, Bellera CL, Di Ianni M, et al. CNS drug development – lost in translation? Mini Rev Med Chem 2012;12:959-70
- Sarter M, Tricklebank M. Revitalizing psychiatric drug discovery. Nat Rev Drug Discov 2012;11:423-4
- Abbott A. The drug deadlock. Nature 2010;468:158-9
- Chandler DJ. Something’s got to give: psychiatric disease on the rise and novel drug development on the decline. Drug Discov Today 2013;18:202-6
- Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6(4):37
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
- Marder SR. Retreat from the radical. Nature 2014;508:S18
- Volkow ND, Wang GJ, Fowler JS, et al. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA 2011;108:15037-42
- O’Leary T, Marder E. Mapping neural activation onto behavior in an entire animal. Science 2014;344:372-92
- Kinch MS, Merkel J, Umlauf S. Trends in pharmaceutical targeting of clinical indications: 1930-2013. Drug Disc Today 2014. [Epub ahead of print]
- FDA/Center for Drug Evaluation and Research. FDA approved drug products. 2014. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [Last accessed 28 July 2014]
- EvaluatePharma. World preview 2014, outlook to 2020. 2014. Available from: http://info.evaluategroup.com/rs/evaluatepharmaltd/images/EP240614.pdf [Last accessed 28 July 2014]
- Fong TW, Reid RC, Parhami I. Behavioral addictions: where to draw the line? Psychiatr Clin North Am 2012;35:279-96
- Karim R, Chaudhri P. Behavioral addictions: an overview. J Psychoactive Drugs 2012;44:5-17
- Grant JE, Schreiber LR, Odlaug BL. Phenomenology and treatment of behavioural addictions. Can J Psychiatry 2013;58:252-9
- Volkow ND, Skolnick P. New medications for substance use disorders: challenges and opportunities. Neuropsychopharmacology 2012;37:290-2
- Potenza MN, Sofuoglu M, Carroll KM, et al. Neuroscience of behavioral and pharmacological treatments for addictions. Neuron 2011;69:695-712
- Litten RZ, Egli M, Heilig M, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 2012;17:513-27
- Pierce RC, O’Brien CP, Kenny PJ, et al. Rational development of addiction pharmacotherapies: successes, failures, and prospects. Cold Spring Harb Perspect Med 2012;2(6):a012880
- Skolnick P, Volkow ND. Addiction therapeutics: obstacles and opportunities. Biol Psychiatry 2012;72:890-1
- Janero DR. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists. Expert Opin Emerg Drugs 2012;17:17-29
- Loftis JM, Huckans M. Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy. Pharmacol Ther 2013;139:289-300
- Uchtenhagen AA. Heroin maintenance treatment: from idea to research to practice. Drug Alcohol Rev 2011;30:130-7
- US Pharmaceutical sales– 2013. 2014. Available from: http://www.drugs.com/stats/top100/2013/sales [Last accessed 28 July 2014]
- Volkow ND, Baler RD. Addiction science: uncovering neurobiological complexity. Neuropharmacology 2014;76:235-49
- Ducci F, Goldman D. The genetic basis of addictive disorders. Psychiatr Clin North Am 2012;35:495-519
- Urban NB, Martinez D. Neurobiology of addiction: insight from neurochemical imaging. Psychiatr Clin North Am 2012;35:521-41
- Caprioli D, Fryer TD, Sawiak SJ, et al. Translating positron emission tomography studies in animals to stimulant addiction: promises and pitfalls. Curr Opin Neurobiol 2013;23:597-606
- Bossers SM, de Boer RD, Boer C, et al. The diagnostic accuracy of brain microdialysis during surgery: a qualitative systematic review. Acta Neurochir (Wien) 2013;155:345-53
- Balan IS, Saladino AJ, Aarabi B, et al. Cellular alterations in human traumatic brain injury: changes in mitochondrial morphology reflect regional levels of injury severity. J Neurotrauma 2013;30:367-81
- Brunner D, Balci F, Ludvig EA. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration. Behav Processes 2012;89:187-95
- Green AR, Gabrielsson J, Fone KCF. Translational neuropharmacology and the appropriate and effective use of animal models. Br J Pharmacol 2011;164:1041-3
- Ersche KD, Turton AJ, Pradhan S, et al. Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits. Biol Psychiatry 2010;68:770-3
- Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 2012;37:11-24
- Jhanjee S. Evidence based psychosocial interventions in substance use. Indian J Psychol Med 2014;36:112-18
- Bardo MT, Neisewander JL, Kelly TH. Individual differences and social influences on the neurobehavioral pharmacology of abused drugs. Pharmacol Rev 2013;65:255-90
- Preskorn SH. CNS drug development: part III: future directions. J Psychiatr Pract 2011;17:49-52
- Nutt D, Goodwin G. ECNP summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol 2011;21:495-9
- Reardon S. NIH rethinks psychiatry trials. Nature 2014;507:288
- Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-19
- Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov 2014;13(8):577-87
- Allen KR. Screening for drugs of abuse: which matrix, oral fluid or urine? Ann Clin Biochem 2011;48:531-41
- Marsden J, Eastwood B, Wright C, et al. How best to measure change in evaluations of treatment for substance use disorder. Addiction 2011;106:294-302
- Maisto SA, Krenek M, Chung T, et al. A comparison of the concurrent and predictive validity of three measures of readiness to change alcohol use in a clinical sample of adolescents. Psychol Assess 2011;23:983-94
- Yapko MD. Treating depression with antidepressants: drug-placebo efficacy debates limit broader considerations. Am J Clin Hypn 2013;55:272-90
- Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013;170:723-33
- Sacks LV, Shamsuddin HH, Yasinskaya YI, et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications of new drugs, 2000-2012. JAMA 2014;311:378-84
- van Boekel LC, Brouwers EP, van Weeghel J, et al. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend 2013;131:23-35
- Wood E, Samet JH, Volkow ND. Physician education in addiction medicine. JAMA 2013;310:1673-4
- Collins PY, Insel TR, Chockalingam A, et al. Grand challenges in global mental health: integration in research, policy, and practice. PLoS One 2013;10:e1001434
- Tai B, Volkow ND. Treatment for substance use disorder: opportunities and challenges under the affordable care act. Soc Work Public Health 2013;28:165-74
- Pecoraro A, Ma M, Woody GE. The science and practice of medication-assisted treatments for opioid dependence. Subst Use Misuse 2012;47:1026-40
- Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J 2009;6:35
- Franck C, Budlovsky T, Windle SB, et al. Electronic cigarettes in North America: history, use, and implications for smoking cessation. Circulation 2014;129:1945-52
- Brushwood DB, Rich BA, Coleman JJ, et al. Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain. J Pain Palliat Care Pharmacother 2010;24:333-48
- Pfizer Pharmaceutical News and Media. Pfizer reports third-quarter 2008 results. 2008. Available from: http://press.pfizer.com/press-release/pfizer-reports-third-quarter-2008-results [Last accessed 28 July 2014]
- Eggertson L. Pfizer advertises smoking cessation drug despite health warnings. CMAJ 2012;184(2):E127-8
- Pfizer, Inc. Annual report pursuant to section 13 or 15(d) of the Securities and Exchange Act of 1934. Form 10-K/A. Amendment No. 1. 2013:107. 2013. Available from: http://assets.fieremarkets.net/public/lifesciences/pfizersecfiling.pdf [Last accessed 28 July 2014]
- Kissin I. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg 2010;110:780-9
- Hornke M, Mandewirth S. Mergers & acquisitions (M&A) in the pharmaceutical industry: the wheel keeps on turning. J Business Chem 2010;7:67-8
- Lowman M, Trott P, Hoecht A, et al. Innovation risks of outsourcing in pharmaceutical new product development. Technovation 2012;32:99-109
- Plumridge H, Loftus P. Inversion frenzy rocks drug sector. Wall Street J 2014. Available from: http://online.wsj.com/articles/drug-maker-abbvie-proposed-merger-with-shire-was-rejected-1403239977 [Last accessed 28 July 2014]
- Preskorn SH. CNS drug development: part I: the early period of CNS drugs. J Psychiatr Pract 2010;16:334-9
- Preskorn SH. CNS drug development: part II: advances from the 1960s to the 1990s. J Psychiatr Pract 2010;16:413-50
- Awouters FH, Lewi PJ. Forty years of antipsychotic drug research–from haloperidol to paliperidone–with Dr. Paul Janssen. Arzneimittelforschung 2007;57:625-32
- Arrowsmith J. A decade of change. Nat Rev Drug Discov 2012;11:17-18
- Verheij MM, Cools AR. Twenty years of dopamine research: individual differences in the response of accumbal dopamine to environmental and pharmacological challenges. Eur J Pharmacol 2008;585:228-44
- Portnow LH, Vaillancourt DE, Okun MS. The history of cerebral PET scanning: from physiology to cutting-edge technology. Neurology 2013;80:952-6
- The Human Brain Project. 2012. Available from: https://www.humanbrainproject.eu/ [Last accessed 28 July 2014]
- Kandel ER, Markram H, Mattthews PM, et al. Neuroscience thinks big (and collaboratively). Nat Rev Neurosci 2013;14:659-64
- Nutt DJ, Kilpatrick GJ, Hayes A. The extinction of drugs for clinical research: can the ECNP medicines chest save them? Eur Neuropsychopharmacol 2014;24:487-90
- Sun J, Hung LC, Xu H, et al. Network-assisted prediction of potential drugs for addiction. Biomed Res Int 2014;2014:258784
- Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract 2011;24:541-50
- Orexigen, Inc. Orexigen receives three month extension of FDA NB32 review. 2014. Available from: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1938944&highlight= [Last accessed 28 July 2014]
- Edwards S, Koob GF. Experimental psychiatric illness and drug abuse models: from human to animal, an overview. Methods Mol Biol 2012;829:31-48
- Horton DB, Potter DM, Mead AN. A translational pharmacological approach to understanding the predictive value of abuse potential assessments. Behav Pharmacol 2013;24:410-36
- Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 2009;1005:S14-25
- Moser P, Wolinsky T, Duxon M, et al. How good are current approaches to nonclinical evaluation of abuse and dependence? J Pharmacol Exp Ther 2011;336:588-95
- Ahmed SH. The science of making drug-addicted animals. Neuroscience 2012;211:107-25
- Holmes EA, Craske MG, Graybiel AM. A call for mental-health science. Nature 2014;511:287-9
- Janero DR, Lindsley L, Vemuri VK, et al. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opin Drug Discov 2011;6:995-1025
- Cahil K, Ussher MH. Cannabinoid type 1 receptor antagonist for smoking cessation. Cochrane Database Syst Rev 2011(3):CD005353
- Erdozain AM, Callado LF. Involvement of the endocannabinoid system in alcohol dependence: the biochemical, behavioral and genetic evidence. Drug Alcohol Depend 2011;117:102-10
- Janero DR. The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential. Expert Opin Drug Discov 2014;9:847-58
- Hargreaves RJ, Rabiner EA. Translational PET imaging research. Neurobiol Dis 2014;61:32-8
- Goonoo N, Bhaw-Luximon A, Ujoodha R, et al. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems. J Control Release 2014;183:154-66
- Ashare RL, Schmidt HD. Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov 2014;9:579-94
- Perkins KA, Lerman C. Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics. Clin Pharmacol Ther 2011;89:460-3
- Agrawal A, Verweij KJ, Gillespie NA, et al. The genetics of addiction– a translational perspective. Transl Psychiatry 2012;2:e140
- Milne C-P, Garafolo S, Bryan C, et al. Trial watch: personalized medicines in late-stage development. Nat Rev Drug Discov 2014;13:324-5
- Nutt DJ, Attridge J. CNS drug development in Europe– past progress and future challenges. Neurobiol Dis 2014;61:6-20
- Johnson GS. Commercial viability of CNS drugs: balancing the risk/reward profile. Neurobiol Dis 2014;61:21-4
- McLellan AT, Woodworth AM. The affordable care act and treatment for “substance use disorders:” implications of ending segregated behavioral healthcare. J Subst Abuse Treat 2014;46:541-5
- A History of Naltrexone. 2014. Available from: http://www.lowdosenaltrexone.org/gazorpa/History.html [Last accessed 28 July 2014]
- Kemp AH, Gordon E, Rush AJ, et al. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008;13:1066-86
- Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalized anxiety disorder: systematic review and meta-analysis. BMJ 2011;342:d1199
- Keating GM. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs 2013;27:761-72
- Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 2013;13:583-609
- Issa NT, Byers SW, Dakshanamurthy S. Drug repurposing: translational pharmacology, chemistry, computers, and the clinic. Curr Top Med Chem 2013;13:2328-36
- Jin G, Wong STC. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014;19:637-64
- Emig D, Ivliev A, Pustovalova O, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One 2013;8:e60618
- Brady LS, Winsky L, Goodman W, et al. NIMH initiatives to facilitate collaborations among industry, academia, and government of the discovery and clinical testing of novel models and drugs for psychiatric disorders. Neuropsychopharmacology 2009;34:229-43
- Campbell ND, Lovell AM. The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci 2012;1248:124-39
- Germann PG, Schuhmacher A, Harrison J, et al. How to create innovation by building the translation bridge from basic research into medical drugs: an industrial perspective. Hum Genomics 2013;7:5
- Gorodetzky CW, Grudzinskas C. Involving the pharmaceutical and biotech communities in medication development for substance abuse. Pharmacol Ther 2005;108:109-18
- Brady LS, Potter WZ. Public-private partnerships to revitalize psychiatric drug discovery. Expert Opin Drug Discov 2014;9:1-8
- Hayden EC. Universities seek to boost industry partnerships. Nature 2014;509:146
- Goldman M. The Innovative Medicines Initiative: a European response to the innovations challenge. Nature 2012;91:418-25
- Janero DR. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca. Expert Opin Drug Discov 2012;7:449-56
- National Center for Advancing Translational Sciences (NCATS). 2014. Available from: http://www.ncats.nih.gov/ [Last accessed 28 July 2014]
- United States Department of Defense. Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR). 2014. Available from: http://www.acq.osd.mil/obsp/sbir/about/index.shtml [Last accessed 28 July 2014]
- Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today 2012;17:1088-102
- GBI Research. Substance abuse therapeutics market to 2018– effective drug therapies in the treatment of alcohol and opioid dependence offer significant market opportunities. 2012. Available from: http://www.marketresearch.com/GBI-research-v3759/Substance-Abuse-Therapeutics-Effective-Drug-7104603/ [Last accessed 28 July 2014]
- United States Food and Drug Administration Advisory Committee Calendar. October 16, 2014: joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement. 2014. Available from: http://www.fda.gov/AdvisoryCommittes/Calendar/ucm394876.htm [Last accessed 28 July 2014]
- Medical News Today. Purdue Pharma, executives plead guilty to misbranding OxyContin, fined $634.5M. 2007. Available from: http://www.medicalnewstoday.com/releases/70753.php [Last accessed 28 July 2014]
- Olsen Y, Sharfstein JM. Chronic pain, addiction, and Zohydro. N Engl J Med 2014;370:2061-3
- Kamp J. New painkiller sparks abuse concern. Wall Street J 2014. Available from: http://online.wsj.com/news/articles/SB10001424052702303749904579580254059253722 [Last accessed 28 July 2014]
- Glover S, Girion L. Counties sue narcotics makers, alleging ‘campaign of deception’. Los Angeles Times; 2014. Available from: http://www.latimes.com/local/la-me-rx-big-pharma-suit-20140522-story.html [Last accessed 28 July 2014]
- Genetic Engineering & Biotechnology News. Chicago sues five opioid makers, linking abuse to marketing. 2014. Available from: http://www.genengnews.com/gen-news-highlights/chicaco-sues-five-opioid-makers-linking-abuse-to-marketing/81249950 [Last accessed 28 July 2014]
- Suboxone Sales Data. 2014. Available from: http://www.drugs.com/stats/suboxone [Last accessed 28 July 2014]